Accord Healthcare launches their first biopharmaceutical product in Europe: Accofil® (filgrastim)
Accord Healthcare is pleased to announce the launch of their first European approved biopharmaceutical product Accofil®, indicated for the treatment of chemotherapy induced neutropenia.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Cost effectiveness Industry News Haematology Oncology biopharmaceutical chemotherapy induced neutropenia filgrastim hiv Latest News peripheral blood progenitor cells Source Type: news
More News: Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Filgrastim | Neulasta | Neupogen